4.5 Article

Correlates and outcomes of depressed out-patients with greater and fewer anxious symptoms: a CO-MED report

期刊

出版社

OXFORD UNIV PRESS
DOI: 10.1017/S1461145711001660

关键词

Anxiety; depression; outcomes; treatment prediction

资金

  1. Abbott Laboratories, Inc.
  2. AstraZeneca
  3. Bristol-Myers Squibb Company (BMS)
  4. Eisai Pharmaceuticals
  5. Janssen
  6. VA, NIMH, Shire
  7. Southwestern Oncology Group, Department of Defense (DoD)
  8. Abbott Laboratories
  9. Alkermes
  10. Aspect Medical Systems
  11. Astra-Zeneca
  12. Bristol-Myers Squibb Company
  13. Cephalon
  14. Forest Pharmaceuticals Inc.
  15. GlaxoSmithKline
  16. J & J Pharmaceuticals
  17. Lichtwer Pharma GmbH
  18. Eli Lilly Company
  19. Lorex Pharmaceuticals
  20. Novartis
  21. Organon Inc.
  22. PamLab, LLC
  23. Pfizer Inc.
  24. Pharmavite
  25. Roche
  26. Sanofi/Synthelabo
  27. Solvay Pharmaceuticals, Inc.
  28. Wyeth-Ayerst Laboratories
  29. Indevus
  30. Pfizer
  31. Sanofi-Aventis
  32. Wyeth-Ayerst
  33. Cyberonics
  34. NorthStar/St. Jude Medical
  35. Medtronics
  36. Repligen
  37. National Institute of Mental Health
  38. Agency for Healthcare Research and Quality
  39. M-3 Information
  40. MGH from NIMH
  41. Pam labs
  42. Pfizer Pharmaceuticals and Shire
  43. Astra Zeneca
  44. Eli Lilly
  45. Janssen Pharmaceuticals
  46. Bristol-Myers Squibb
  47. University of Michigan, Brain Resource
  48. Otsuka Pharmaceuticals
  49. royalties from Guilford Publications
  50. University of Texas Southwestern Medical Center
  51. Cephalon, Inc.
  52. Corcept Therapeutics, Inc.
  53. Cyberonics, Inc.
  54. Forest Pharmaceuticals
  55. Janssen Pharmaceutica
  56. Merck
  57. National Alliance for Research in Schizophrenia and Depression
  58. Pharmacia Upjohn
  59. Predix Pharmaceuticals

向作者/读者索取更多资源

The objective of this paper was to determine whether the presence of more vs. fewer anxious symptom features, at baseline, are associated with other clinical features and treatment outcomes in out-patients with major depressive disorder (MDD). This single-blind, randomized trial enrolled 665 MDD outpatients to compare the efficacy of two antidepressant medication combinations against escitalopram after 12-wk acute treatment and follow-up (total 28 wk). The sample was divided into those with greater (vs. fewer) anxiety features using the anxiety/somatization subscale of the baseline 17-item Hamilton Rating Scale for Depression. Baseline sociodemographic and clinical features, treatment features and outcomes compared these two groups. Overall, 74.7% of participants met the threshold for 'anxious features'. They were more likely to be female, have other concurrent anxiety disorders, more severe depression, more lethargic and melancholic features and poorer cognitive and physical functioning, quality of life and work and social adjustment. In acute treatment, participants with anxious features received comparatively higher doses of mirtazapine and venlafaxine and reported more side-effects. The groups with and without anxious features did not differ in treatment outcomes and side-effect burden. Despite being associated with a distinct clinical profile, baseline anxious features were not clinically useful in predicting acute treatment outcomes or differential treatment response.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据